At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 589 enrolled
Drug / intervention
Sumatriptan and Naproxen Sodium +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
TXA107979: A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a Combination Product Containing Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine in Adolescents
In Brief
A Phase 3 clinical trial evaluating Sumatriptan and Naproxen Sodium and Placebo for Migraine Disorders. Completed, enrolled 589 participants across 79 sites.
Detailed Summary
This study was designed to determine how well the combination medication, sumatriptan and naproxen sodium, treats migraine headache in adolescents 12-17 years old
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine Disorders
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2008
First PostedFeb 2009
Primary CompletionMay 2010
Study CompletionJun 2010
TodayJul 2026
First PostedFeb 13, 2009
Enrollment StartDec 1, 2008
Primary CompletionMay 1, 2010
Study CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 17.4 years ago
Interventions
Sumatriptan and Naproxen Sodiumdrug
Sumatriptan succinate and naproxen sodium
Placebodrug
Placebo to match